PODCAST

Critical Care

ReachMD

science & medicine medicine

All Episodes

00:00:00

Pharmacy Perspectives: Real-World Management of...

Critical Care ·

2023/03/31

Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP Patients presenting to the hospital with severe bleeding and underlying treatment with Factor Xa (FXa) or Factor IIa inhibitors represent an enormous challenge to providers and clinicians since the approvals of apixaban, edoxaban, rivaroxaban, and dabigatran within the United States. Intracranial bleeding, intra-abdominal or thoracic trauma, gastrointestinal bleeding, and bleeding from any non-compressible source represent true

00:00:00

Hematoma Expansion and Clinical Outcomes Comparison...

Critical Care ·

2023/03/31

Host: Natalie Kreitzer, MD, MS Patients presenting to the hospital with severe bleeding and underlying treatment with Factor Xa (FXa) or Factor IIa inhibitors represent an enormous challenge to providers and clinicians since the approvals of apixaban, edoxaban, rivaroxaban, and dabigatran within the United States. Intracranial bleeding, intra-abdominal or thoracic trauma, gastrointestinal bleeding, and bleeding from any non-compressible source represent true life-threatening

00:00:00

Comparing In-hospital Mortality With Andexanet Alfa...

Critical Care ·

2023/03/31

Host: Gregory J. Fermann, MD Patients presenting to the hospital with severe bleeding and underlying treatment with Factor Xa (FXa) or Factor IIa inhibitors represent an enormous challenge to providers and clinicians since the approvals of apixaban, edoxaban, rivaroxaban, and dabigatran within the United States. Intracranial bleeding, intra-abdominal or thoracic trauma, gastrointestinal bleeding, and bleeding from any non-compressible source represent true life-threatening emergencies

00:00:00

Andexanet Alfa Is Associated With Lower In-Hospital...

Critical Care ·

2023/03/31

00:00:00

Life-Threatening Bleeding in the Anticoagulated...

Critical Care ·

2023/03/31

00:00:00

ANNEXa-I: Recent Advances in the Treatment of...

Critical Care ·

2023/03/31

00:00:00

GI Bleeding and DOACs: Consensus Panel Findings

Critical Care ·

2023/03/31

00:00:00

Summary of Real-World Data for Treatment of Oral...

Critical Care ·

2023/03/31

00:00:00

Clinical Implications of ANNEXa-I on the Management...

Critical Care ·

2023/03/31

Host: W. Brian Gibler, MD, FACEP, FACC, FAHA Host: Gregory J. Fermann, MD Host: Natalie Kreitzer, MD, MS Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP Patients presenting to the hospital with severe bleeding and underlying treatment with Factor Xa (FXa) or Factor IIa inhibitors represent an enormous challenge to providers and clinicians since the approvals of apixaban, edoxaban, rivaroxaban, and dabigatran within the United States. Intracranial bleeding,

00:00:00

Emergency Medicine Perspectives: Targeted vs....

Critical Care ·

2023/03/31

Host: Gregory J. Fermann, MDPatients presenting to the hospital with severe bleeding and underlying treatment with Factor Xa (FXa) or Factor IIa inhibitors represent an enormous challenge to providers and clinicians since the approvals of apixaban, edoxaban, rivaroxaban, and dabigatran within the United States. Intracranial bleeding, intra-abdominal or thoracic trauma, gastrointestinal bleeding, and bleeding from any non-compressible source represent true life-threatening emergencies

10 results

Critical Care

All Episodes

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事